# Compass Pathways outlines potential 30- to 60-day FDA review target as it plans to complete COMP360 NDA in next 2 weeks

- Source: Seeking Alpha Market Currents
- Published: 2026-11-03T17:47:04+00:00
- Category: Markets
- Original: https://seekingalpha.com/news/4663860-compass-pathways-outlines-potential-30-to-60-day-fda-review-target-as-it-plans-to-complete?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
- Canonical: https://groundlevelnews.com/story/compass-pathways-outlines-potential-30-to-60-day-fda-review-target-as--a644ed/

Read the full report from the original publisher.

_Ground Level News shows a short summary only; the full article and all rights belong to Seeking Alpha Market Currents._